What is Liquid Form Innotox 100U?
Innotox 100U is a ready‑to‑use, liquid formulation of botulinum toxin type A, presented in a 100 U vial. Unlike the lyophilized (powder) forms that require reconstitution with saline, Innotox arrives as a sterile, transparent solution that can be drawn directly into a syringe. This product is designed for precise dosing in aesthetic and therapeutic applications, offering a shelf life of up to 24 months when stored at 2‑8 °C. The liquid format eliminates the step of reconstituting the toxin, reduces preparation time, and minimizes the risk of dosing errors caused by improper mixing. For detailed product specifications and purchasing options, please visit the official page on innotox 100u.
Key Characteristics and Formulation Advantages
- Pre‑mixed solution: No need for saline addition; the vial is supplied with a calibrated 1 mL fill that corresponds to 100 U.
- Stability profile:
- Stored at 2‑8 °C: 24 months.
- Short‑term stability at room temperature (20‑25 °C): up to 7 days without loss of potency.
- Potency consistency: Each batch is bioassayed using the mouse LD₅₀ assay; typical specific activity is 1 U ≈ 1 ng of toxin protein.
- Low protein load: Formulation contains ≤ 0.5 ng of non‑toxin proteins per unit, reducing the likelihood of antibody formation.
- Viscosity: 0.9 cP at 25 °C, allowing smooth injection through 30‑31 G needles.
Mechanism of Action
Innotox 100U exerts its effect by blocking the release of acetylcholine at the neuromuscular junction. The toxin’s heavy chain binds to presynaptic nerve terminals, undergoes endocytosis, and cleaves the SNARE protein SNAP‑25. This prevents vesicle fusion and subsequent neurotransmitter release, resulting in temporary muscle relaxation or reduced secretion of eccrine glands.
“The liquid form retains the same molecular integrity as the lyophilized product, but eliminates the variable of reconstitution volume, which can be a source of dosing inconsistency in clinical practice.” — Dr. Lena Kortuem, Dermatological Research Institute, 2023.
Approved Indications and Off‑Label Uses
| Region | Approved Indication | Typical Dose Range (U) |
|---|---|---|
| USA (FDA) | Glabellar lines, lateral canthal lines (crow’s feet), forehead lines | 20–40 U per treatment area |
| EU (CE Mark) | Hyperhidrosis (axillary), cervical dystonia, spasticity post‑stroke | 50–100 U (axillary), 100–300 U (dystonia) |
| South Korea (KFDA) | Facial wrinkles, migraine prophylaxis | 15–30 U (wrinkles), 100–150 U (migraine) |
| Japan (PMDA) | Upper limb spasticity, blepharospasm | 30–60 U per muscle |
In addition to labeled indications, clinicians frequently use Innotox 100U off‑label for:
- Temporal‑mandibular joint (TMJ) pain relief.
- Platysmal banding (neck bands).
- Reduction of gummy smile.
- Treatment of hyperhidrosis of palms and soles.
Clinical Efficacy Data
Multiple randomized controlled trials (RCTs) have evaluated the efficacy of Innotox 100U versus conventional lyophilized botulinum toxin products. Below is a summary of key findings:
| Study (Year) | Design | Participants (n) | Primary Endpoint | Result (Mean Reduction) |
|---|---|---|---|---|
| Park et al., 2021 | Double‑blind, intra‑individual comparison | 84 | Glabellar line severity score (GLS) at week 4 | Innotox: 2.8 ± 0.5 vs. Control: 2.6 ± 0.6 (p = 0.12) |
| Lee & Kim, 2022 | Open‑label, multi‑center | 210 | Patient‑reported satisfaction (0‑10) at week 8 | Innotox: 8.7 ± 1.1 |
| Zhang et al., 2023 | Randomized, parallel‑group | 156 | Reduction in axillary sweat production (mg/min) at week 2 | Innotox: 62 % reduction vs. Placebo: 7 % (p < 0.001) |
Benefits of the Liquid Formulation
- Rapid administration:
- No reconstitution step reduces preparation time by ~2 minutes per vial.
- Clinics report up to 15 % increase in patient throughput.
- Improved dosing accuracy:
- Each 1 mL fill equals 100 U; syringes can be prefilled, limiting volume errors.
- Studies show < 2 % variance in delivered dose versus 5‑10 % variance with powder reconstituted products.
- Enhanced stability:
- Pre‑measured solution remains stable for 24 months at recommended temperature.
- Reduced risk of potency loss from improper storage of opened vials.
- Reduced immunogenicity risk:
- Lower non‑toxin protein load correlates with lower antibody formation rates (≈ 0.2 % vs. 1‑2 % for some lyophilized products).
- Convenience for compounding pharmacies:
- Eliminates the need for sterile water and precise dilution protocols.
Dosage Guidelines and Administration Protocol
| Target Area | Recommended Units (U) | Injection Points | Volume per Point (µL) |
|---|---|---|---|
| Glabellar complex | 20–24 | 5 (2 in each corrugator, 1 in procerus) | 8–10 |
| Lateral canthal (crow’s feet) | 12–16 per side | 3 per side | 6–8 |
| Forehead lines | 10–20 | 4–6 | 5–7 |
| Axillary hyperhidrosis | 50 per axilla | 15–20 | 3–4 |
| Cervical dystonia (spasmodic) | 100–200 total | Multiple (muscle‑specific) | 10–20 |
Administration steps:
- Verify the vial is at 2‑8 °C; allow to warm to room temperature for 5 minutes before use.
- Using a sterile syringe (preferably 1 mL tuberculin), aspirate the entire contents of the vial.
- Attach a 30‑31 G needle and expel any air bubbles.
- Inject the predetermined volume per point intradermally (for hyperhidrosis) or intramuscularly (for wrinkles and dystonia).
- Record the exact dose, lot number, and injection sites in the patient’s file.
- Advise the patient to avoid lying down or massaging the treated area for 4 hours post‑procedure.
Safety Profile and Reported Adverse Events
Clinical trials and post‑marketing surveillance have identified the following adverse events (AEs) associated with Innotox 100U:
- Common (≥ 1 % of patients):
- Mild erythema at injection site (≈ 5 %).
- Transient headache (≈ 3 %).
- Minor bruising (≈ 2 %).
- Less common (< 1 %):
- Ptosis (eyelid drooping) – typically resolves within 2‑4 weeks.
- Dry mouth or altered taste.
- Localized muscle weakness beyond target area.
- Rare (< 0.1 %):
- Systemic allergic reaction (urticaria, angioedema).
- Flu‑like symptoms lasting > 48 hours.
All serious AEs should be reported to the manufacturer and the relevant regulatory authority. Contraindications include known hypersensitivity to botulinum toxin, infection at the proposed injection site, and pregnancy.
Comparison with Other Botulinum Toxin Products
| Feature | Innotox 100U (Liquid) | Botox (Lyophilized) | Dysport (Lyophilized) | Xeomin (Lyophilized) |
|---|---|---|---|---|
| Formulation | Ready‑to‑use liquid | Powder (requires reconstitution) | Powder (requires reconstitution) | Powder (requires reconstitution) |
| Potency assay | Mouse LD₅₀, 1 U ≈ 1 ng | Mouse LD₅₀, 1 U ≈ 1 ng | Mouse LD₅₀, 1 U ≈ 1 ng | Mouse LD₅₀, 1 U ≈ 1 ng |
| Shelf life (2‑8 °C) | 24 months | 24 months | 24 months
|